Ertapenem

Ertapenem 구조식 이미지
카스 번호:
153832-46-3
상품명:
Ertapenem
동의어(영문):
Ertapenem hydrochloride;MK-0826;EOS-61119;ERTAPENEM;Ertapenem D4;Ertapenem Powder;Ertapenem Monomer;Ertapenem USP/EP/BP;ERTAPENEM(FORR&DONLY);ErtapenemDiscontinued See E635000
CBNumber:
CB0722982
분자식:
C22H25N3O7S
포뮬러 무게:
475.51
MOL 파일:
153832-46-3.mol

Ertapenem 속성

끓는 점
813.9±65.0 °C(Predicted)
밀도
1.55±0.1 g/cm3(Predicted)
저장 조건
2-8°C
용해도
메탄올,DMSO에 용해됨
산도 계수 (pKa)
4.03±0.10(Predicted)
물리적 상태
포말 모양
색상
갈색
InChIKey
JUZNIMUFDBIJCM-ANEDZVCMSA-N
SMILES
N12[C@@]([H])([C@@H]([C@H](O)C)C1=O)[C@@H](C)C(S[C@H]1C[C@@H](C(NC3=CC=CC(C(O)=O)=C3)=O)NC1)=C2C(O)=O
CAS 데이터베이스
153832-46-3
안전
  • 위험 및 안전 성명
  • 위험 및 사전주의 사항 (GHS)
유해 물질 데이터 153832-46-3(Hazardous Substances Data)
그림문자(GHS): Exclamation Mark (GHS07)
신호 어: Warning
유해·위험 문구:
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드
H302 삼키면 유해함 급성 독성 물질 - 경구 구분 4 경고 P264, P270, P301+P312, P330, P501
H315 피부에 자극을 일으킴 피부부식성 또는 자극성물질 구분 2 경고 P264, P280, P302+P352, P321,P332+P313, P362
H319 눈에 심한 자극을 일으킴 심한 눈 손상 또는 자극성 물질 구분 2A 경고 P264, P280, P305+P351+P338,P337+P313P
H335 호흡 자극성을 일으킬 수 있음 특정 표적장기 독성 - 1회 노출;호흡기계 자극 구분 3 경고
예방조치문구:
P261 분진·흄·가스·미스트·증기·...·스프레이의 흡입을 피하시오.
P305+P351+P338 눈에 묻으면 몇 분간 물로 조심해서 씻으시오. 가능하면 콘택트렌즈를 제거하시오. 계속 씻으시오.

Ertapenem C화학적 특성, 용도, 생산

개요

Ertapenem is another synthetic carbapenem with a rather complex side chain at C-3. It is used once daily parenterally, with special application against anaerobes. As with meropenem, the 4-β-methyl group confers stability toward dehydropeptidase-1 It is not active against pseudomonads or acinetobacteria and, therefore, should not be substituted for imipenem or meropenem. It is relatively strongly bound to serum proteins, so it has a prolonged half-life, making it more convenient to use than the other carbapenems when its spectrum warrants this. Its reported indications include complicated intra-abdominal and complicated skin/skin structure infections caused by sensitive organisms (for intra-abdominal: Escheri chia coli, Clostri di um clostri doforme, Bacteroi des fragilis, and Peptostreptococcus sp; for skin/skin structures: Staphylococcus aureus (methicillin-susceptible strains), Streptococcus pyogenes, E.coli, or Peptostreptococcus sp.). It can be administered once daily.

용도

Ertapenem is a long-acting parenteral cabapenem. Ertapenem has bactericidal activity against a variety of gram-negative pathogens, some gram positive strains, and Haemopilus influenzae. Ertapenem has shown to inactivate L,D-transpeptidase, an enzyme responsible for in vitro cross-linking of Mycobacterium tuberculosis peptidoglycan.

정의

ChEBI: Meropenem in which the one of the two methyl groups attached to the amide nitrogen is replaced by hydrogen while the other is replaced by a 3-carboxyphenyl group. The sodium salt is used for the treatment of moderate to severe susceptible infections includ ng intra-abdominal and acute gynaecological infections, pneumonia, and infections of the skin and of the urinary tract.

Antimicrobial activity

Activity against aerobic and anaerobic pathogens is comparable to that of imipenem: MIC values for Gramnegative bacilli (with the exception of Ps. aeruginosa) are generally lower and those for Gram-positive cocci higher.
Ertapenem is stable to most serine β-lactamases, but is hydrolyzed by serine carbapenemases and metallo- β-lactamases.

일반 설명

Ertapenem (Invanz, for injection) is a synthetic 1-β-methylcarbapenem that is structurally related to β-lactam antibiotics,particularly the thienamycin group. Its mechanism ofaction is the same as that of other β-lactam antibiotics. Thestructure resists β-lactamases and dehydropeptidases.
Ertapenem is indicated for the treatment of moderate tosevere infections caused by susceptible strains causing complicatedintra-abdominal infections such as Escherichia,Clostridium, Peptostreptococcus, and Bacteroides. Theantibiotic is also indicated for complicated skin and skinstructure infections including diabetic foot infections (withoutosteomyelitis). Treatable strains include Staphylococcus(MSSA), Streptococcus, Escherichia, Klebsiella, Proteus,and Bacteroides. Ertapenem is also indicated for community-acquired pneumonia caused by S. pneumoniae,Haemophilus infljuenzae, and M. catarrhalis. Complicatedurinary tract infections and acute pelvic infections round outthe indications for ertapenem.

Pharmacokinetics

Cmax 1 g intramuscular: c. 67 mg/L after 2 h
1 g intravenous infusion (30 min): c. 155 mg/L end infusion
Plasma half-life: c. 4 h
Volume of distribution: c. 0.12 L/kg (steady state)
Plasma protein binding: 85–95%
Absorption after intramuscular injection is essentially complete with 90% bioavailability. The modestly extended plasma half-life allows once-daily dosing.
Excretion is predominantly by the renal route, about 80% being recovered in the urine within 24 h. About 40% is eliminated unchanged, the rest as a biologically inactive ringopened metabolite. Dosage should be reduced in severe renal impairment.

Clinical Use

Complicated intra-abdominal infections
Complicated skin and skin structure infections, including diabetic foot
infections without osteomyelitis
Community acquired pneumonia
Complicated urinary tract infections including pyelonephritis
Acute pelvic infections including postpartum endomyometritis, septic
abortion and postsurgical gynecologic infections
Prophylaxis of surgical site infection following elective colorectal surgery

부작용

Ertapenem appears to be generally well tolerated. The most common drug-related adverse experiences are diarrhea (5.5%), infused vein complication (3.7%), nausea (3.1%), headache (2.2%), vaginitis (2.1%), phlebitis/thrombophlebitis (1.3%) and vomiting (1.1%). Seizures have occasionally been reported (0.5%) in patients with a history of disorders of the CNS.

Ertapenem 준비 용품 및 원자재

원자재

준비 용품


Ertapenem 공급 업체

글로벌( 182)공급 업체
공급자 전화 이메일 국가 제품 수 이점
Suizhou HongQi Chemical Corporation Limited 0722-3257376 13026100080;13235518175;
774811011@qq.com China 60 55
wangyubin@starunimed.com 18328380615
youchaochris@starunimed.com China 374 58
J & K SCIENTIFIC LTD. 18210857532 18210857532
jkinfo@jkchemical.com China 96815 76
shilang(zhuoli group)-pharma(nanjing) co.,ltd. 86-25-87797880,81,82 -809
shilang@shilang-pharma.com China 40 55
Beijing HwrkChemical Technology Co., Ltd 89508211 18501085097
sales.bj@hwrkchemical.com China 9409 55
Adamas Reagent, Ltd. 4006009262 13023226327
hmj@titansci.com China 14098 59
LGM Pharma 1-(800)-881-8210
inquiries@lgmpharma.com United States 2110 70
Shanghai Longsheng chemical Co.,Ltd. 58099637 13585536065
sales@shlschem.com China 9880 59
XiaoGan ShenYuan ChemPharm co,ltd 15527621225; 15527621225
1791901229@qq.com China 6717 52
China Langchem Inc. 0086-21-58956006
China 7798 57

Ertapenem 관련 검색:

Copyright 2019 © ChemicalBook. All rights reserved